Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Decrease in Short Interest

Posted by Brenda Bartman on Aug 27th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 4,171 shares, a decrease of 75.2% from the July 30th total of 16,792 shares. Based on an average trading volume of 8,523 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the shares of the stock are short sold.

Pulmatrix Stock Down 0.3%

Shares of NASDAQ:PULM traded down $0.01 during midday trading on Thursday, hitting $1.52. The stock had a trading volume of 14,050 shares, compared to its average volume of 11,902. The company’s 50-day moving average price is $1.64 and its 200-day moving average price is $1.69. Pulmatrix has a fifty-two week low of $1.16 and a fifty-two week high of $5.50. The company has a market capitalization of $5.55 million, a P/E ratio of -1.38 and a beta of 1.91.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.00) by $1.71.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Research Report on PULM

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new stake in shares of Pulmatrix during the third quarter worth about $52,000. DRW Securities LLC bought a new position in Pulmatrix in the 4th quarter valued at $46,000. Finally, BlackRock Inc. purchased a new stake in Pulmatrix during the second quarter worth about $93,000. 11.84% of the stock is owned by institutional investors.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).